Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
Company expects strong organic growth in sales, EBITDA in 2022
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Subscribe To Our Newsletter & Stay Updated
